MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment

Completed
Conditions
Atrial Fibrillation
First Posted Date
2020-06-17
Last Posted Date
2023-02-08
Lead Sponsor
Pfizer
Target Recruit Count
109
Registration Number
NCT04435769
Locations
🇨🇿

Fakultní nemocnice Motol, Praha 5, Czechia

Global Prevalence of ATTR-CM in Participants With HFpEF

Not Applicable
Terminated
Conditions
Heart Failure With Preserved Ejection Fraction
Transthyretin Amyloid Cardiomyopathy
Interventions
Diagnostic Test: Scintigraphy
First Posted Date
2020-06-11
Last Posted Date
2024-07-19
Lead Sponsor
Pfizer
Target Recruit Count
347
Registration Number
NCT04424914
Locations
🇺🇸

Advance Medical Research Center, Miami, Florida, United States

🇺🇸

Bioclinical Research Alliance Inc., Miami, Florida, United States

🇺🇸

Biogenix Molecular, Miami, Florida, United States

and more 47 locations

Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients

Completed
Conditions
Arthritis, Rheumatoid
Interventions
First Posted Date
2020-06-11
Last Posted Date
2021-09-09
Lead Sponsor
Pfizer
Target Recruit Count
1493
Registration Number
NCT04428424
Locations
🇮🇶

Pfizer, Baghdad, Iraq

Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

Completed
Conditions
Plaque Psoriasis
Interventions
First Posted Date
2020-06-11
Last Posted Date
2021-10-25
Lead Sponsor
Pfizer
Target Recruit Count
486
Registration Number
NCT04428411
Locations
🇮🇶

Pfizer, Baghdad, Iraq

Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)

Completed
Conditions
Psoriatic Arthritis
Interventions
First Posted Date
2020-06-11
Last Posted Date
2021-09-14
Lead Sponsor
Pfizer
Target Recruit Count
127
Registration Number
NCT04428502
Locations
🇮🇶

Pfizer, Baghdad, Iraq

Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2020-06-11
Last Posted Date
2022-07-21
Lead Sponsor
Pfizer
Target Recruit Count
8
Registration Number
NCT04427917
Locations
🇧🇪

Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

Recruiting
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2020-06-09
Last Posted Date
2025-04-13
Lead Sponsor
Pfizer
Target Recruit Count
280
Registration Number
NCT04424303
Locations
🇫🇷

Clinique de l Europe, Amiens, France

🇫🇷

Hopital D'Estaing, Clermont Ferrand, France

🇫🇷

Hopital Sud, Amiens, France

and more 35 locations

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Phase 3
Completed
Conditions
Respiratory Tract Infection
Interventions
Biological: Placebo
First Posted Date
2020-06-09
Last Posted Date
2025-02-11
Lead Sponsor
Pfizer
Target Recruit Count
14727
Registration Number
NCT04424316
Locations
🇺🇸

Pocatello Women's Health Clinic, Pocatello, Idaho, United States

🇺🇸

1st Choice Urgent Care, Pocatello, Idaho, United States

🇺🇸

The Iowa Clinic, Ankeny, Iowa, United States

and more 433 locations

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
First Posted Date
2020-06-04
Last Posted Date
2023-04-07
Lead Sponsor
Pfizer
Target Recruit Count
460
Registration Number
NCT04413617
Locations
🇧🇬

Independent Medical Diagnostic Laboratory Mediscan EOOD, Plovdiv, Bulgaria

🇧🇬

MHAT Plovdiv AD, Plovdiv, Bulgaria

🇧🇬

DCC Sveti Georgi EOOD, Plovdiv, Bulgaria

and more 140 locations

Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

Phase 2
Withdrawn
Conditions
COVID-19
Interventions
Other: Placebo
First Posted Date
2020-06-02
Last Posted Date
2020-07-31
Lead Sponsor
Pfizer
Registration Number
NCT04412252
Locations
🇺🇸

LSUHSC-Shreveport, Shreveport, Louisiana, United States

🇺🇸

Ochsner LSU Health Shreveport Academic Medical Center, Shreveport, Louisiana, United States

🇺🇸

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath